//
Hope Rugo
Sherene Loi
Sylvia Adams
Peter Schmid
Andreas Schneeweiss
Carlos H Barrios
Hiroji Iwata
Vronique Diras
Eric P Winer
Mark M Kockx
Dieter Peeters
Stephen Y Chui
Jennifer C Lin
Anh Nguyen Duc
Guiseppe Viale
Luciana Molinero
Leisha A Emens
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Peter MacCallum Cancer Centre, East Melbourne, Australia
NYU Langone Medical Center, New York, NY
Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
University Hospital Heidelberg and German Cancer Research Center, Heidelberg, Germany
Centro de Pesquisa Clínica, HSL, PUCRS, Porto Alegre, Brazil
Aichi Cancer Center Hospital, Nagoya, Japan
Departments of Medical Oncology and Radiotherapy, Centre Eugene Marquis, Rennes, France
Dana-Farber Cancer Institute, Boston, MA
HistoGeneX, Antwerp, Belgium
Genentech, Inc., South San Francisico, CA
F. Hoffmann-La Roche Ltd., Basel, Switzerland
University of Milano-Bicocca and European Institute of Oncology, Milano, Italy
University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA
United States
Australia
United Kingdom
Germany
Brazil
Japan
France
Belgium
Switzerland
Italy
Genentech, Inc.
F. Hoffmann-La Roche
Oncology (ONC)
Triple-negative breast cancer
Programmed death-ligand 1
SP263
N/A
N/A
III
NCT02425891
N/A
N/A